Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308425 | PMC |
http://dx.doi.org/10.3389/fimmu.2020.01132 | DOI Listing |
Background: Rearranged during transfection () fusions represent a distinct molecular subset of non-small cell lung cancer (NSCLC) with targeted therapeutic potential. Selpercatinib, a highly selective inhibitor, has demonstrated efficacy in various solid tumors harboring alterations. Here, we present a case highlighting the use and clinical outcomes of selpercatinib in a patient diagnosed with advanced lung adenocarcinoma harboring a fusion.
View Article and Find Full Text PDFFront Immunol
January 2025
State Key Laboratory of Membrane Biology, School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Institute for Immunology, China Ministry of Education Key Laboratory of Protein Sciences, Beijing, China.
Front Cell Infect Microbiol
January 2025
State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.
Front Physiol
January 2025
Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom.
Introduction: Chronic fetal hypoxia is commonly associated with fetal growth restriction and can predispose to respiratory disease at birth and in later life. Antenatal antioxidant treatment has been investigated to overcome the effects of oxidative stress to improve respiratory outcomes. We aimed to determine if the effects of chronic fetal hypoxia and antenatal antioxidant administration persist in the lung in early adulthood.
View Article and Find Full Text PDFBMJ Nutr Prev Health
November 2024
Department of Child Health, University of Ghana Medical School, College of Health Sciences, Accra, Ghana.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!